Jefferies Financial Group Inc. Sells 18,615 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Jefferies Financial Group Inc. reduced its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 53.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 16,000 shares of the pharmaceutical company’s stock after selling 18,615 shares during the period. Jefferies Financial Group Inc.’s holdings in Vertex Pharmaceuticals were worth $6,266,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Chesapeake Asset Management LLC boosted its holdings in shares of Vertex Pharmaceuticals by 110.0% during the 3rd quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock valued at $25,000 after purchasing an additional 33 shares during the last quarter. Colonial Trust Co SC increased its holdings in shares of Vertex Pharmaceuticals by 118.8% in the third quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 38 shares during the last quarter. Total Investment Management Inc. purchased a new stake in shares of Vertex Pharmaceuticals in the second quarter worth about $33,000. Financial Network Wealth Advisors LLC boosted its stake in Vertex Pharmaceuticals by 50.9% during the third quarter. Financial Network Wealth Advisors LLC now owns 86 shares of the pharmaceutical company’s stock valued at $34,000 after buying an additional 29 shares during the last quarter. Finally, Y.D. More Investments Ltd boosted its stake in Vertex Pharmaceuticals by 345.0% during the third quarter. Y.D. More Investments Ltd now owns 89 shares of the pharmaceutical company’s stock valued at $35,000 after buying an additional 69 shares during the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 4,500 shares of the firm’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $474.99, for a total value of $2,137,455.00. Following the transaction, the executive vice president owned 42,293 shares in the company, valued at approximately $20,088,752.07. This trade represents a 9.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Amit Sachdev sold 58,613 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $468.83, for a total value of $27,479,532.79. Following the transaction, the executive vice president owned 58,934 shares in the company, valued at approximately $27,630,027.22. The trade was a 49.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 91,156 shares of company stock worth $42,845,497 in the last ninety days. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX opened at $460.87 on Tuesday. The company’s 50-day simple moving average is $467.50 and its 200-day simple moving average is $435.79. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $362.50 and a fifty-two week high of $519.68. The stock has a market capitalization of $117.07 billion, a P/E ratio of 30.06 and a beta of 0.31.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.The business had revenue of $3.19 billion for the quarter, compared to analysts’ expectations of $3.18 billion. During the same quarter in the previous year, the firm posted $3.98 EPS. Vertex Pharmaceuticals’s revenue was up 9.5% on a year-over-year basis. On average, research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Key Headlines Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: RAINIER interim results: The company said a pre‑specified Week‑36 interim analysis of the Phase 3 RAINIER trial of povetacicept met the primary objective and all secondary endpoints, citing meaningful efficacy vs. placebo in adults with IgA nephropathy — the core catalyst driving the move. Business Wire release
• Positive Sentiment: Analyst reinforcement: William Blair’s Myles Minter reiterated a Buy and said confidence in povetacicept’s profile has increased after the RAINIER readout, strengthening the bullish investment case for VRTX. Analyst backing amplifies the positive reaction. TipRanks/William Blair note
• Positive Sentiment: Perception of high commercial potential: Coverage notes that povetacicept — acquired in a multibillion‑dollar deal — could be a best‑in‑class therapy in a competitive kidney disease market, supporting a longer‑term revenue upside if full data and approvals follow. BioPharmaDive article
• Neutral Sentiment: Market reaction and headlines: Media and trading outlets reported a sharp after‑hours/share surge following the announcement; that immediate momentum reflects sentiment but may be volatile as investors digest details and next steps. Benzinga coverage
• Negative Sentiment: Ongoing uncertainty: These are interim results from an ongoing trial — final RAINIER readout, safety follow‑up, regulatory timelines and payer/commercial execution remain unknown. Investors should weigh upside against the risk that final data or regulatory review could change the outlook. Yahoo Finance release

Analysts Set New Price Targets

A number of research firms have issued reports on VRTX. UBS Group lifted their price objective on Vertex Pharmaceuticals from $535.00 to $545.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Stifel Nicolaus lifted their price objective on shares of Vertex Pharmaceuticals from $445.00 to $466.00 and gave the stock a “hold” rating in a research note on Friday, February 13th. Barclays boosted their price objective on Vertex Pharmaceuticals from $606.00 to $607.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 17th. Morgan Stanley reiterated an “overweight” rating and issued a $570.00 target price on shares of Vertex Pharmaceuticals in a report on Friday, February 13th. Finally, Sanford C. Bernstein reiterated an “outperform” rating and set a $577.00 price objective on shares of Vertex Pharmaceuticals in a research report on Friday, February 13th. Twenty-two investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $542.00.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.